Aliases & Classifications for Tic Disorder

MalaCards integrated aliases for Tic Disorder:

Name: Tic Disorder 12 15 71
Behavioral Tic 71
Tics 6

Classifications:



External Ids:

Disease Ontology 12 DOID:2769
ICD9CM 34 307.20
MeSH 43 D013981
SNOMED-CT 67 568005
ICD10 32 F95 F95.9
UMLS 71 C0040188 C0278076

Summaries for Tic Disorder

Disease Ontology : 12 A specific developmental disorder that is characterized by the persistent presence of involuntary brief movements or sounds occuring intermittently and unpredictably out of a background of normal motor activity.

MalaCards based summary : Tic Disorder, also known as behavioral tic, is related to chronic tic disorder and obsessive-compulsive disorder, and has symptoms including ataxia, myoclonus and tremor. An important gene associated with Tic Disorder is DRD4 (Dopamine Receptor D4), and among its related pathways/superpathways are Circadian entrainment and Beta-Adrenergic Signaling. The drugs Acetylcholine and Clopidogrel have been mentioned in the context of this disorder. Affiliated tissues include brain, breast and testes, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 74 Tic disorders are defined in the Diagnostic and Statistical Manual of Mental Disorders (DSM) based on... more...

Related Diseases for Tic Disorder

Diseases in the Tic Disorder family:

Chronic Tic Disorder Transient Tic Disorder

Diseases related to Tic Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 394)
# Related Disease Score Top Affiliating Genes
1 chronic tic disorder 34.3 SLITRK1 IMMP2L DRD5 DRD4 DRD3 DRD2
2 obsessive-compulsive disorder 31.9 TPH2 SLITRK5 SLITRK1 SLC6A3 DRD4 DRD3
3 gilles de la tourette syndrome 31.6 SLITRK5 SLITRK1 SLC6A3 PVALB NRXN1 NLGN4X
4 oppositional defiant disorder 31.2 TPH2 SLC6A3 DRD4 DRD2
5 anxiety 30.8 TPH2 SLC6A3 PRODH DRD4 DRD3 DRD2
6 conduct disorder 30.7 SLC6A3 DRD5 DRD4 DRD2
7 attention deficit-hyperactivity disorder 30.6 TPH2 SLC6A3 PRODH NLGN4X IMMP2L DRD5
8 paroxysmal dystonia 30.6 SLC6A3 PVALB PNKD
9 early-onset schizophrenia 30.5 DRD2 DRD1
10 tardive dyskinesia 30.5 DRD3 DRD2
11 generalized anxiety disorder 30.4 SLC6A3 PRODH DRD2
12 alcohol use disorder 30.4 SLC6A3 DRD3 DRD2 DRD1
13 movement disease 30.4 SLC6A3 PRODH PNKD DRD5 DRD4 DRD3
14 obsessive-compulsive personality disorder 30.4 SLITRK1 DRD3
15 hemidystonia 30.4 PNKD DRD2
16 personality disorder 30.4 TPH2 SLC6A3 DRD4 DRD3 DRD2
17 choreatic disease 30.4 PNKD DRD5 DRD4 DRD3 DRD2 DRD1
18 stereotypic movement disorder 30.3 SLITRK1 PRODH
19 echolalia 30.3 NRXN1 NLGN4X CNTNAP2
20 sexual disorder 30.3 DRD4 DRD3 DRD2
21 cyclothymic disorder 30.3 DRD4 DRD2
22 trichotillomania 30.3 SLITRK5 SLITRK1 MIR24-1 DRD4 DRD3 DRD2
23 focal dystonia 30.2 PNKD DRD5 DRD2 DRD1
24 mood disorder 30.2 TPH2 SLC6A3 PRODH DRD4 DRD3 DRD2
25 bruxism 30.2 DRD5 DRD3 DRD2 DRD1
26 eating disorder 30.1 SLC6A3 DRD3 DRD2
27 stuttering 30.1 SLC6A3 PVALB DRD2 CNTNAP2
28 oculogyric crisis 30.1 DRD5 DRD4 DRD3 DRD2 DRD1
29 asperger syndrome 30.0 NRXN1 NLGN4X CNTNAP2
30 avoidant personality disorder 30.0 SLC6A3 DRD4
31 speech disorder 30.0 PVALB PRODH DRD2 CNTNAP2
32 panic disorder 29.9 TPH2 SLC6A3 DRD5 DRD4 DRD3 DRD2
33 restless legs syndrome 29.9 SLC6A3 DRD5 DRD4 DRD3 DRD2 DRD1
34 alcohol dependence 29.9 TPH2 SLC6A3 DRD5 DRD4 DRD3 DRD2
35 dystonia 29.9 SLC6A3 PVALB PNKD DRD5 DRD3 DRD2
36 dyslexia 29.8 SLC6A3 IMMP2L DRD4 DRD3 DRD2 CNTNAP2
37 migraine with or without aura 1 29.8 SLC6A3 PNKD DRD5 DRD4 DRD3 DRD2
38 fragile x syndrome 29.8 PVALB PRODH NRXN1 NLGN4X MIR24-1 DLGAP3
39 substance abuse 29.7 SLC6A3 PRODH DRD5 DRD4 DRD3 DRD2
40 impulse control disorder 29.4 SLITRK5 SLITRK1 SLC6A3 DRD5 DRD4 DRD3
41 autism spectrum disorder 29.4 TPH2 SLC6A3 PRODH NRXN1 NLGN4X IMMP2L
42 disease of mental health 29.3 SLC6A3 PVALB PRODH NRXN1 MIR24-1 DRD5
43 autism 29.2 TPH2 SLC6A3 PRODH NRXN1 NLGN4X IMMP2L
44 psychotic disorder 28.9 TPH2 SLC6A3 PVALB PRODH NRXN1 MIR24-1
45 bipolar disorder 28.9 TPH2 SLC6A3 PVALB PRODH NRXN1 DRD5
46 schizophrenia 28.7 TPH2 SLC6A3 PVALB PRODH NRXN1 NLGN4X
47 pervasive developmental disorder 28.4 TPH2 SLC6A3 PVALB PRODH NRXN1 NLGN4X
48 transient tic disorder 12.8
49 trigeminal neuralgia 12.2
50 pediatric acute-onset neuropsychiatric syndrome 11.4

Graphical network of the top 20 diseases related to Tic Disorder:



Diseases related to Tic Disorder

Symptoms & Phenotypes for Tic Disorder

UMLS symptoms related to Tic Disorder:


ataxia, myoclonus, tremor, dystonia, athetosis, symptoms, synkinesis, recurrent muscle twitches (symptom), tic, motor, tic, gestural, tic, transient, tic, vocal

GenomeRNAi Phenotypes related to Tic Disorder according to GeneCards Suite gene sharing:

26 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.58 DRD4
2 Increased shRNA abundance (Z-score > 2) GR00366-A-13 9.58 PRODH
3 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.58 DRD4
4 Increased shRNA abundance (Z-score > 2) GR00366-A-148 9.58 PRODH
5 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.58 DRD3
6 Increased shRNA abundance (Z-score > 2) GR00366-A-172 9.58 DRD4
7 Increased shRNA abundance (Z-score > 2) GR00366-A-2 9.58 PRODH
8 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.58 PRODH
9 Increased shRNA abundance (Z-score > 2) GR00366-A-33 9.58 PRODH
10 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.58 DRD3
11 Increased shRNA abundance (Z-score > 2) GR00366-A-56 9.58 DRD4
12 Increased shRNA abundance (Z-score > 2) GR00366-A-58 9.58 DRD3 DRD4 PRODH
13 Increased shRNA abundance (Z-score > 2) GR00366-A-66 9.58 PRODH
14 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.58 PRODH
15 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.58 PRODH
16 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.58 PRODH

MGI Mouse Phenotypes related to Tic Disorder:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.16 CNTNAP2 DLGAP3 DRD1 DRD2 DRD3 DRD4
2 nervous system MP:0003631 9.86 CNTNAP2 DLGAP3 DRD1 DRD2 DRD3 DRD4
3 integument MP:0010771 9.85 CNTNAP2 DLGAP3 DRD1 DRD2 HDC IMMP2L
4 taste/olfaction MP:0005394 8.92 CNTNAP2 DRD2 SLC6A3 TPH2

Drugs & Therapeutics for Tic Disorder

Drugs for Tic Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 189)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
2
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
3
Ticagrelor Approved Phase 4 274693-27-5 9871419
4
Donepezil Approved Phase 4 120014-06-4 3152
5
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
6
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
7
Levetiracetam Approved Phase 4 102767-28-2 441341
8
Clonidine Approved Phase 4 4205-90-7 2803
9
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
10
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
11
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
12
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
13
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
14
Riluzole Approved, Investigational Phase 4 1744-22-5 5070
15
Fluvoxamine Approved, Investigational Phase 4 54739-18-3 3404 5324346
16
Haloperidol Approved Phase 4 52-86-8 3559
17
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
18
Desflurane Approved Phase 4 57041-67-5 42113
19
Ondansetron Approved Phase 4 99614-02-5 4595
20
Atorvastatin Approved Phase 4 134523-00-5 60823
21
Galantamine Approved Phase 4 357-70-0 9651
22
Choline Approved, Nutraceutical Phase 4 62-49-7 305
23
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
24 Liver Extracts Phase 4
25 Purinergic P2Y Receptor Antagonists Phase 4
26 Vasodilator Agents Phase 4
27 Dopamine Antagonists Phase 4
28 Antidepressive Agents Phase 4
29 Adrenergic alpha-Agonists Phase 4
30 Antihypertensive Agents Phase 4
31 Adrenergic Agents Phase 4
32 Sympatholytics Phase 4
33 Adrenergic Agonists Phase 4
34 Anticonvulsants Phase 4
35 Protective Agents Phase 4
36 Serotonin Uptake Inhibitors Phase 4
37 Analgesics, Non-Narcotic Phase 4
38 Platelet Aggregation Inhibitors Phase 4
39 Neuroprotective Agents Phase 4
40 Excitatory Amino Acid Antagonists Phase 4
41 Cytochrome P-450 Enzyme Inhibitors Phase 4
42 Haloperidol decanoate Phase 4
43 Neurotransmitter Agents Phase 4
44 Psychotropic Drugs Phase 4
45 Antipsychotic Agents Phase 4
46 Dermatologic Agents Phase 4
47 Gastrointestinal Agents Phase 4
48 Antiemetics Phase 4
49 Anti-Anxiety Agents Phase 4
50 Antimetabolites Phase 4

Interventional clinical trials:

(show top 50) (show all 177)
# Name Status NCT ID Phase Drugs
1 Phase 4 Study of Long Term Postoperative Cognitive Dysfunction After Laparoscopic Cholecystectomy in the Elderly Patients Unknown status NCT02301676 Phase 4 Sevoflurane;propofol
2 Comparison of TIcagrelor and Clopidogrel in Patients With Coronary Artery diseaSe and Type 2 Diabetes Mellitus (TICS-DM): a Randomized Pharmacodynamic Study Unknown status NCT02457130 Phase 4 Ticagrelor;Clopidogrel
3 Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Unknown status NCT01098383 Phase 4 Acetyl-Choline Esterase Inhibitors and Choline supplements;Indistinguishable placebo tablets, matching both donepezil and choline
4 Open Label Trial of Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT00241176 Phase 4 Aripiprazole
5 A Placebo Controlled Trial of Amoxicillin for Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections Completed NCT00001658 Phase 4 Amoxicillin
6 Comparison of Keppra and Clonidine in the Treatment of Tics in Children With Tourette Syndrome Completed NCT00370838 Phase 4 Levetiracetam;Clonidine
7 Guanfacine in Children With Tic Disorders: A Multi-site Study Completed NCT01547000 Phase 4 placebo;extended-release guanfacine (Intuniv)
8 A 12-Week, Double-Blind Trial of Olanzapine and Placebo in the Treatment of Trichotillomania Completed NCT00182507 Phase 4 Olanzapine
9 Rivastigmine in the Treatment of Postoperative Delirium: a Pilot Clinical Trial Completed NCT00835159 Phase 4 Rivastigmine Patch
10 Impact of Dexmedetomidine Sedation on the Post-Operative Cognition Dysfunction——a Multiple Center,Randomized, Controlled,Double Blinded Clinical Trial. Completed NCT02275182 Phase 4 Dexmedetomidine;Saline
11 Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission Completed NCT01018056 Phase 4 D-serine;Riluzole;Placebo
12 Neurobiology/Treatment of Obsessive-Compulsive Disorder Completed NCT00000373 Phase 4 olanzapine + fluoxetine;placebo + fluoxetine
13 Recovery Following Desflurane vs Sevoflurane for Outpatient Urologic Surgery in Elderly Females Completed NCT01310582 Phase 4 Desflurane;Sevoflurane
14 Effects of Ondansetron in Obsessive-compulsive and Tic Disorders Recruiting NCT03239210 Phase 4 Ondansetron;Placebo
15 The Effect of Ramelteon on Delirium and Sleep in Patients Admitted to the ICU Recruiting NCT03931070 Phase 4 Ramelteon;Placebo - Cap
16 PRagmatic EValuation of evENTs And Benefits of Lipid-lowering in oldEr Adults (PREVENTABLE) Not yet recruiting NCT04262206 Phase 4 Atorvastatin 40 Mg Oral Tablet;Placebo oral tablet
17 Pilot Examination of Galantamine in the Management of Tic Disorders Terminated NCT00226824 Phase 4 galantamine
18 A Randomized, Double-blind, Dose-adjustment, Placebo-controlled Study to Evaluate the Efficacy and Safety of Aripiprazole in Children and Adolescents With Chronic Tic Disorders or Tourette's Disorder Completed NCT00706589 Phase 3 aripiprazole;placebo
19 A 3-arm Phase III Study of 5LGr, Tiapride or Placebo in Pediatric Patients With Tic Disorder Completed NCT01501695 Phase 3 5LGr;tiapride;placebo
20 Behavior Therapy for Children With Chronic Tic Disorders Completed NCT00218777 Phase 2, Phase 3
21 A Well-Controlled, Fixed-Dose Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tics Associated With Tourette Syndrome Completed NCT03571256 Phase 3 TEV-50717;Placebo
22 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder Completed NCT00004376 Phase 3 guanfacine
23 An Open-Label, Multicenter Study Evaluating the Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01727713 Phase 3 Aripiprazole
24 A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Fixed-Dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01727700 Phase 3 Aripiprazole;Placebo
25 A Randomized, Double-Blind, Placebo-Controlled Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents Completed NCT03452943 Phase 2, Phase 3 TEV-50717;Placebo
26 A Placebo-Controlled Trial of Intravenous Immunoglobulin (IVIG) for PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections) Completed NCT01281969 Phase 3 Gamunex Intravenous Immunoglobulin;Placebo
27 Long-term Safety and Effectiveness of OROS (Methylphenidate HCl) in Children With ADHD Completed NCT00269815 Phase 3 methylphenidate HCl
28 Multicenter Study Comparing the Efficacy and Safety of OROS (Methylphenidate HCl), Ritalin, and Placebo in Children With ADHD Completed NCT00269802 Phase 3 OROS methylphenidate HCl;Ritalin;Placebo
29 An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome (CAPSS-286) Completed NCT00206336 Phase 3 Topiramate (drug)
30 Comparative Crossover Study of OROS (Methylphenidate HCl), Ritalin, and Placebo in Children With ADHD Completed NCT00269789 Phase 3 Ritalin;OROS Methylphenidate HCl;Placebo
31 Screening, Efficacy, and Safety Study Evaluating OROS (Methylphenidate HCl), Ritalin and Placebo in Children With ADHD Completed NCT00269776 Phase 3 Placebo;OROS (methylphenidate HCl);Ritalin (methylphenidate)
32 Treatment of Gilles de la Tourette Syndrome by Bilateral Stimulation of the Internal Part of the Globus PALLIDUS Completed NCT00478842 Phase 3
33 A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Determine the Safety and Efficacy of Topiramate in the Treatment of Tourette Syndrome (CAPSS-176) Completed NCT00206323 Phase 3 Topiramate (drug);placebo/sugar pill
34 A Randomized Multi-centre Double-blind Placebo Controlled Trial to Demonstrate the Efficacy and Safety of Nabiximols in the Treatment of Adults With Chronic Tic Disorders Recruiting NCT03087201 Phase 3 nabiximols;placebo
35 The Impact of Vitamin K2 and Inactive Vitamin D Supplementation on Vascular Calcification in Pediatric Patients on Regular Hemodialysis Recruiting NCT04145492 Phase 2, Phase 3 Vitamin K2;Cholecalciferol (inactive vitamin D);Vitamin K2 and Cholecalciferol
36 An Open-Label, Long-Term Safety Study Including a Double-Blind, Placebo-Controlled, Randomized Withdrawal Period of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents Active, not recruiting NCT03567291 Phase 3 TEV-50717;Placebo
37 Metformin in Alzheimer's Dementia Prevention Not yet recruiting NCT04098666 Phase 2, Phase 3 Placebo oral tablet;extended release metformin
38 Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years Unknown status NCT02102698 Phase 2 Ecopipam
39 Optimising Anterior Pallidal Deep Brain Stimulation for Tourette's Syndrome - A Pilot Study Unknown status NCT02112253 Phase 1, Phase 2
40 Antibiotic Treatment and Intravenous Immunoglobulin Double-blind, Randomized, Placebo-controlled Trial for PANDAS Unknown status NCT01769027 Phase 2 Sertraline+Antibiotic (penicillin/azithromycin);Sertraline+placebo
41 TIBOHCA: A Single-centre, Phase II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of 2-Iminobiotin (2-IB) After Out of Hospital Cardiac Arrest Unknown status NCT02836340 Phase 1, Phase 2 2-Iminobiotin
42 rTMS Over the Supplementary Motor Area for Treatment-resistant Obsessive-compulsive Disorder: a Multicenter, Double-blind, Controlled Trial. Unknown status NCT03211221 Phase 2
43 Behavior Therapy and Psychosocial Treatment for Tourette Syndrome and Chronic Tic Disorder Completed NCT00231985 Phase 2
44 A Randomized, Placebo-Controlled Study of ABX-1431 in Adult Patients With Tourette Syndrome or Chronic Motor Tic Disorder Completed NCT03625453 Phase 2 ABX-1431;Placebo
45 Voice Over Internet Protocol Delivered Behavior Therapy for Tourette Syndrome Completed NCT02247206 Phase 2
46 A Trial of Prophylaxis for the PANDAS Subgroup Completed NCT00001359 Phase 2 Penicillin or Placebo
47 Double-Blind, Placebo-Controlled Trial of N-acetylcysteine (NAC) for the Treatment of Children With Tourette Syndrome Completed NCT01172288 Phase 2 N-Acetylcysteine (NAC);Placebo
48 Subthalamic Nucleus Deep Brain Stimulation in Tourette's Syndrome Completed NCT02619084 Phase 2
49 Open Label Safety and Tolerability Trial of CPP-109 (Vigabatrin) in Adults With Treatment Refractory Tourette's Disorder Completed NCT01585207 Phase 1, Phase 2 vigabatrin
50 A 6-month, Multicenter, Randomized, Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder Completed NCT01904773 Phase 2 AZD5213 and placebo

Search NIH Clinical Center for Tic Disorder

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Clonazepam

Genetic Tests for Tic Disorder

Anatomical Context for Tic Disorder

MalaCards organs/tissues related to Tic Disorder:

40
Brain, Breast, Testes, Liver, Lung, Prostate, Globus Pallidus

Publications for Tic Disorder

Articles related to Tic Disorder:

(show top 50) (show all 4520)
# Title Authors PMID Year
1
Cerebrospinal fluid endocannabinoid levels in Gilles de la Tourette syndrome. 61
32272483 2020
2
Use of Complementary and Alternative Medicine in Children With Tourette Syndrome. 61
32233737 2020
3
Deep slow nasal respiration with tight lip closure for immediate attenuation of severe tics. 61
32417125 2020
4
Hispidulin attenuates the social withdrawal in isolated disrupted-in-schizophrenia-1 mutant and chronic phencyclidine-treated mice. 61
32133633 2020
5
Comorbidity and Factors Affecting Treatment Non-Persistence in ADHD. 61
26006168 2020
6
Pneumoparotid and Pneumoparotitis: A Literary Review. 61
32498334 2020
7
Frequency-Agile Low-temperature Solution-Processed Alumina Dielectrics for Inorganic and Organic Electronics Enhanced by Fluoride Doping. 61
32539371 2020
8
Tumor-insular Complex in Neoadjuvant Treated Pancreatic Ductal Adenocarcinoma Is Associated With Higher Residual Tumor. 61
32091434 2020
9
Polyglycerol-based Thermoresponsive Nanocapsules Induce Skin Hydration and Serve as Skin Penetration Enhancer. 61
32519848 2020
10
Prevalence and clinical correlates of self-injurious behavior in Tourette syndrome. 61
32205150 2020
11
Entraining Movement-Related Brain Oscillations to Suppress Tics in Tourette Syndrome. 61
32502412 2020
12
Experiences of Tourette Syndrome Caregivers With Supportive Communication. 61
32476565 2020
13
Contrast-Enhanced Ultrasound Findings and Differential Diagnosis of Hepatic Epithelioid Angiomyolipoma Compared with Hepatocellular Carcinoma. 61
32165015 2020
14
Developing the Premonitory Urges for Tic Disorders Scale-Revised (PUTS-R). 61
32543110 2020
15
Increased perception-action binding in Tourette syndrome. 61
32464659 2020
16
Hippocampal Volume in Provisional Tic Disorder Predicts Tic Severity at 12-Month Follow-up. 61
32503289 2020
17
Common neuronal mechanisms underlying tics and hyperactivity. 61
32244155 2020
18
Sleep difficulties in children with Tourette syndrome and chronic tic disorders: a systematic review of characteristics and associated factors. 61
31859345 2020
19
Randomized, Sham-Controlled Trial of Real-Time Functional Magnetic Resonance Imaging Neurofeedback for Tics in Adolescents With Tourette Syndrome. 61
31668476 2020
20
Sex and psychiatric comorbidity correlates of the premonitory urge for tic scale in youth with persistent tic disorders. 61
32212016 2020
21
Lacosamide-Induced Dyskinesia in Children With Intractable Epilepsy. 61
32524876 2020
22
Proteins and Molecular Pathways Relevant for the Malignant Properties of Tumor-Initiating Pancreatic Cancer Cells. 61
32503348 2020
23
Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database. 61
32546134 2020
24
An Overview of the Electroencephalographic (EEG) Features of Epilepsy with Eyelid Myoclonia (Jeavons Syndrome). 61
32369428 2020
25
G9a regulates tumorigenicity and stemness through genome-wide DNA methylation reprogramming in non-small cell lung cancer. 61
32552834 2020
26
[Rolf Hassler: from leucotomy to stereotaxy]. 61
32548758 2020
27
Drugs Targeting Tumor-Initiating Cells Prolong Survival in a Post-Surgery, Post-Chemotherapy Ovarian Cancer Relapse Model. 61
32575908 2020
28
Antibodies From Children With PANDAS Bind Specifically to Striatal Cholinergic Interneurons and Alter Their Activity. 61
32539528 2020
29
Personality and stress influence vision restoration and recovery in glaucoma and optic neuropathy following alternating current stimulation: implications for personalized neuromodulation and rehabilitation. 61
32547650 2020
30
Botulinum Toxin for the Treatment of Motor and Phonic Tics: A Case Report. 61
31906695 2020
31
Neurodevelopmental Disorders: Sensing Tourette's Tics Away. 61
32574629 2020
32
p53 destabilizing protein skews asymmetric division and enhances NOTCH activation to direct self-renewal of TICs. 61
32555153 2020
33
Pediatric Prevention: Tic Disorders. 61
32443993 2020
34
Development of metal adaptation in a tropical marine zooplankton. 61
32576953 2020
35
Carbamazepine-, Oxcarbazepine-, Eslicarbazepine-Associated Movement Disorder: A Literature Review. 61
32384309 2020
36
Novel contrast agent Visphere™ is feasible for contrast-enhanced ultrasonography in dogs. 61
32441861 2020
37
Individual differences in stereotypy and neuron subtype translatome with TrkB deletion. 61
32366954 2020
38
Interventions for tic disorders: An updated overview of systematic reviews and meta analyses. 61
32163785 2020
39
The association between general childhood psychopathology and adolescent suicide attempt and self-harm: A prospective, population-based twin study. 61
32271026 2020
40
Detection of miR-155-5p and imaging lung cancer for early diagnosis: in vitro and in vivo study. 61
32447486 2020
41
Tackle your Tics: pilot findings of a brief, intensive group-based exposure therapy program for children with tic disorders. 61
32436035 2020
42
Sleep disorders in tourette syndrome. 61
32554211 2020
43
Paediatric deep brain stimulation: ethical considerations in malignant Tourette syndrome. 61
32366702 2020
44
KBG syndrome: Common and uncommon clinical features based on 31 new patients. 61
32124548 2020
45
Deep Brain Stimulation for Gilles de la Tourette Syndrome: Toward Limbic Targets. 61
32429219 2020
46
Cell fate, metabolic reprogramming and lncRNA of tumor-initiating stem-like cells induced by alcohol. 61
32171851 2020
47
Treatment of tics associated with Tourette syndrome. 61
31955299 2020
48
Medical and Surgical Treatments of Tourette Syndrome. 61
32279714 2020
49
The cognitive neuropsychiatry of Tourette syndrome. 61
32372718 2020
50
A feasibility study for somatomotor cortical mapping in Tourette syndrome using neuronavigated transcranial magnetic stimulation. 61
32474291 2020

Variations for Tic Disorder

ClinVar genetic disease variations for Tic Disorder:

6 ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 46;XY;t(3;18)(q13.31;q22.1)dnTranslocation Pathogenic 268039
2 46;X;t(Y;16)(q11.23;p11.2);t(6;21)(p21.3;p13)dnTranslocation Likely pathogenic 267834

Expression for Tic Disorder

Search GEO for disease gene expression data for Tic Disorder.

Pathways for Tic Disorder

GO Terms for Tic Disorder

Cellular components related to Tic Disorder according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 10.01 SLC6A3 NRXN1 NLGN4X DRD5 DRD4 DRD3
2 cell junction GO:0030054 9.99 SLITRK1 NRXN1 NLGN4X DRD1 DLGAP3 CNTNAP2
3 dendrite GO:0030425 9.89 NLGN4X DRD4 DRD2 DRD1 CNTNAP2
4 glutamatergic synapse GO:0098978 9.7 SLITRK1 NRXN1 DRD4 DRD3 DRD2 DRD1
5 endocytic vesicle GO:0030139 9.65 NRXN1 DRD3 DRD2
6 ciliary membrane GO:0060170 9.63 DRD5 DRD2 DRD1
7 integral component of postsynaptic membrane GO:0099055 9.61 SLC6A3 DRD2 DRD1
8 synapse GO:0045202 9.61 SLITRK5 SLITRK1 NRXN1 NLGN4X DRD5 DRD3
9 integral component of presynaptic membrane GO:0099056 9.56 SLC6A3 NRXN1 DRD2 DRD1
10 non-motile cilium GO:0097730 9.54 DRD5 DRD2 DRD1
11 9+0 non-motile cilium GO:0097731 9.52 DRD5 DRD1
12 dopaminergic synapse GO:0098691 9.5 SLC6A3 DRD3 DRD2
13 GABA-ergic synapse GO:0098982 9.02 SLITRK1 NRXN1 DRD3 DRD2 DRD1

Biological processes related to Tic Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 64)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 10.04 SLITRK5 NRXN1 NLGN4X DRD5 DRD4
2 response to drug GO:0042493 10.03 SLC6A3 DRD3 DRD2 DRD1
3 cell-cell signaling GO:0007267 10.01 DRD5 DRD3 DRD2 DRD1
4 locomotory behavior GO:0007626 9.93 SLC6A3 DRD3 DRD2 DRD1
5 learning GO:0007612 9.93 NRXN1 NLGN4X DRD3 DRD1 CNTNAP2
6 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.92 DRD5 DRD3 DRD2 DRD1
7 response to ethanol GO:0045471 9.91 SLC6A3 DRD3 DRD2
8 cellular calcium ion homeostasis GO:0006874 9.9 DRD5 DRD4 DRD3
9 axonogenesis GO:0007409 9.9 SLITRK5 SLITRK1 DRD2
10 synapse assembly GO:0007416 9.89 SLITRK1 NRXN1 DRD2 DRD1
11 social behavior GO:0035176 9.88 NRXN1 NLGN4X DRD4 DRD3 CNTNAP2
12 positive regulation of synapse assembly GO:0051965 9.87 SLITRK5 SLITRK1 NRXN1
13 visual learning GO:0008542 9.85 DRD3 DRD2 DRD1
14 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway GO:0051482 9.85 DRD3 DRD2 DRD1
15 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.85 DRD5 DRD3 DRD2 DRD1
16 associative learning GO:0008306 9.83 DRD5 DRD2 DRD1
17 negative regulation of blood pressure GO:0045776 9.83 DRD5 DRD3 DRD2
18 negative regulation of protein secretion GO:0050709 9.81 DRD4 DRD3 DRD2
19 arachidonic acid secretion GO:0050482 9.81 DRD4 DRD3 DRD2
20 behavioral response to cocaine GO:0048148 9.81 DRD4 DRD3 DRD2 DRD1
21 transmission of nerve impulse GO:0019226 9.8 DRD5 DRD1 CNTNAP2
22 dopamine metabolic process GO:0042417 9.8 DRD4 DRD3 DRD2 DRD1
23 response to cocaine GO:0042220 9.8 SLC6A3 DRD5 DRD3 DRD2 DRD1
24 negative regulation of voltage-gated calcium channel activity GO:1901386 9.79 DRD4 DRD3 DRD2
25 vocalization behavior GO:0071625 9.78 NRXN1 NLGN4X CNTNAP2
26 behavioral response to ethanol GO:0048149 9.77 DRD4 DRD3 DRD2
27 grooming behavior GO:0007625 9.76 SLITRK5 DRD2 DRD1
28 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.76 DRD5 DRD3 DRD2 DRD1
29 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.75 DRD5 DRD3 DRD1
30 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.74 DRD4 DRD3 DRD2
31 response to iron ion GO:0010039 9.73 SLC6A3 DRD2
32 negative regulation of cytosolic calcium ion concentration GO:0051481 9.73 DRD3 DRD2
33 long-term synaptic depression GO:0060292 9.73 DRD5 DRD1
34 neuron cell-cell adhesion GO:0007158 9.73 NRXN1 NLGN4X
35 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.73 DRD3 DRD2 DRD1
36 striatum development GO:0021756 9.73 SLITRK5 DRD2 DRD1 CNTNAP2
37 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.72 DRD3 DRD2
38 positive regulation of renal sodium excretion GO:0035815 9.72 DRD3 DRD2
39 G protein-coupled receptor internalization GO:0002031 9.72 DRD3 DRD2
40 response to amphetamine GO:0001975 9.72 DRD5 DRD4 DRD3 DRD2 DRD1
41 regulation of postsynaptic neurotransmitter receptor internalization GO:0099149 9.71 DRD4 DRD3
42 presynaptic membrane assembly GO:0097105 9.71 NRXN1 NLGN4X
43 regulation of potassium ion transport GO:0043266 9.71 DRD3 DRD2
44 postsynaptic membrane assembly GO:0097104 9.71 NRXN1 NLGN4X
45 peristalsis GO:0030432 9.7 DRD2 DRD1
46 adenohypophysis development GO:0021984 9.7 SLC6A3 DRD2
47 hyaloid vascular plexus regression GO:1990384 9.7 SLC6A3 DRD2
48 mating behavior GO:0007617 9.7 DRD5 DRD1
49 response to histamine GO:0034776 9.7 DRD4 DRD3 DRD2
50 cellular response to catecholamine stimulus GO:0071870 9.69 DRD5 DRD1

Molecular functions related to Tic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 drug binding GO:0008144 9.62 SLC6A3 DRD4 DRD3 DRD2
2 adrenergic receptor activity GO:0004935 9.46 DRD5 DRD3 DRD2 DRD1
3 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.43 DRD4 DRD3 DRD2
4 dopamine neurotransmitter receptor activity, coupled via Gs GO:0001588 9.37 DRD5 DRD1
5 dopamine neurotransmitter receptor activity GO:0004952 9.35 DRD5 DRD4 DRD3 DRD2 DRD1
6 dopamine binding GO:0035240 9.1 SLC6A3 DRD5 DRD4 DRD3 DRD2 DRD1

Sources for Tic Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....